Maxipime

Pyelonephritis, Pneumonia, Pneumonia + 7 more
Treatment
18 FDA approvals
20 Active Studies for Maxipime

What is Maxipime

CefepimeThe Generic name of this drug
Treatment SummaryCefepime is an antibiotic used to treat severe bacterial infections. It was developed in 1994 and works by killing bacteria that cause infections. Cefepime is more effective than third-generation antibiotics and can be used to treat pneumonia, infections caused by resistant bacteria, and low white blood cell counts.
Maxipimeis the brand name
image of different drug pills on a surface
Maxipime Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Maxipime
Cefepime
1996
53

Approved as Treatment by the FDA

Cefepime, also known as Maxipime, is approved by the FDA for 18 uses including Complicated Urinary Tract Infection and Severe Pneumonia .
Complicated Urinary Tract Infection
Severe Pneumonia
Uncomplicated Urinary Tract Infections
uncomplicated skin and subcutaneous tissue bacterial infections
Urinary Tract Infection (UTI)
Complicated Intra-Abdominal Infections (cIAIs)
Used to treat Complicated Intra-Abdominal Infections (cIAIs) in combination with Metronidazole
moderate Pneumonia
Pneumonia
Febrile Neutropenia
Bacterial Infections
Pyelonephritis
Urinary tract infection
Pneumonia
Urinary tract infection
Bacterial Infections
Abdominal Infection
Used to treat Complicated Intra-Abdominal Infections (cIAIs) in combination with Metronidazole
Pyelonephritis
Febrile Neutropenia

Effectiveness

How Maxipime Affects PatientsCefepime is an antibiotic that is used to treat certain types of bacterial infections. It is effective against both Gram-positive (e.g. Staphylococcus aureus) and Gram-negative (e.g. Escherichia coli and Pseudomonas aeruginosa) bacteria. It is not affected by certain enzymes that break down other antibiotics, giving it an advantage over other antibiotics. To be effective, the amount of cefepime in the patient's system needs to be higher than the amount of bacteria. Studies have shown that it can cross the blood-brain barrier and can also
How Maxipime works in the bodyCefepime kills bacteria by targeting proteins responsible for building bacterial cell walls. These proteins, known as penicillin-binding proteins, are disrupted by Cefepime, which causes the cell wall to weaken and the bacteria to die. Cefepime is effective against a wide range of Gram-positive and Gram-negative bacteria. It has a particularly strong affinity for three types of penicillin-binding proteins in Escherichia coli and Pseudomonas aeruginosa, as well as two types of proteins in Enterobacter cloacae.

When to interrupt dosage

The advised dosage of Maxipime is contingent upon the diagnosed condition, such as Urinary Tract Infection (UTI), Abdominal Infection and Urinary tract infection. The amount of dosage fluctuates as per the technique of delivery (e.g. Powder, for solution - Intravenous or Injection, powder, for solution - Intravenous) outlined in the table beneath.
Condition
Dosage
Administration
Pneumonia
100.0 mg/mL, , 200.0 mg/mL, 1000.0 mg, 2000.0 mg, 500.0 mg, 100000.0 mg, 1.0 mg/mg, 2.0 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution - Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous
Bacterial Infections
100.0 mg/mL, , 200.0 mg/mL, 1000.0 mg, 2000.0 mg, 500.0 mg, 100000.0 mg, 1.0 mg/mg, 2.0 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution - Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous
Urinary tract infection
100.0 mg/mL, , 200.0 mg/mL, 1000.0 mg, 2000.0 mg, 500.0 mg, 100000.0 mg, 1.0 mg/mg, 2.0 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution - Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous
Urinary tract infection
100.0 mg/mL, , 200.0 mg/mL, 1000.0 mg, 2000.0 mg, 500.0 mg, 100000.0 mg, 1.0 mg/mg, 2.0 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution - Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous
Meningitis, Bacterial
100.0 mg/mL, , 200.0 mg/mL, 1000.0 mg, 2000.0 mg, 500.0 mg, 100000.0 mg, 1.0 mg/mg, 2.0 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution - Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous
Abdominal Infection
100.0 mg/mL, , 200.0 mg/mL, 1000.0 mg, 2000.0 mg, 500.0 mg, 100000.0 mg, 1.0 mg/mg, 2.0 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution - Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous
Pyelonephritis
100.0 mg/mL, , 200.0 mg/mL, 1000.0 mg, 2000.0 mg, 500.0 mg, 100000.0 mg, 1.0 mg/mg, 2.0 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution - Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous
Pneumonia
100.0 mg/mL, , 200.0 mg/mL, 1000.0 mg, 2000.0 mg, 500.0 mg, 100000.0 mg, 1.0 mg/mg, 2.0 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution - Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous
Urinary Tract Infection (UTI)
100.0 mg/mL, , 200.0 mg/mL, 1000.0 mg, 2000.0 mg, 500.0 mg, 100000.0 mg, 1.0 mg/mg, 2.0 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution - Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous
Febrile Neutropenia
100.0 mg/mL, , 200.0 mg/mL, 1000.0 mg, 2000.0 mg, 500.0 mg, 100000.0 mg, 1.0 mg/mg, 2.0 mg/mg
, Intravenous, Injection, solution, Injection, solution - Intravenous, Intramuscular; Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intramuscular; Intravenous, Injection, powder, for solution - Intravenous, Injection, Injection - Intramuscular; Intravenous, Injection - Intravenous, Powder, for solution, Powder, for solution - Intravenous, Powder, for solution - Intramuscular; Intravenous

Warnings

Maxipime has two contraindications and should not be administered while suffering from any of the conditions listed in the below table.Maxipime Contraindications
Condition
Risk Level
Notes
Severe Hypersensitivity Reactions
Do Not Combine
Cefepime may interact with Pulse Frequency
Severe Hypersensitivity Reactions
Do Not Combine
Cefepime may interact with Pulse Frequency
There are 20 known major drug interactions with Maxipime.
Common Maxipime Drug Interactions
Drug Name
Risk Level
Description
Neomycin
Major
The risk or severity of nephrotoxicity can be increased when Cefepime is combined with Neomycin.
Tenofovir
Major
Cefepime may increase the nephrotoxic activities of Tenofovir.
Tenofovir alafenamide
Major
Cefepime may increase the nephrotoxic activities of Tenofovir alafenamide.
Tenofovir disoproxil
Major
Cefepime may increase the nephrotoxic activities of Tenofovir disoproxil.
Vibrio cholerae CVD 103-HgR strain live antigen
Major
The therapeutic efficacy of Vibrio cholerae CVD 103-HgR strain live antigen can be decreased when used in combination with Cefepime.
Maxipime Toxicity & Overdose RiskTaking too much cefepime may cause changes in consciousness, jerking muscle movements, seizures, and long-lasting seizures. If the patient has kidney problems, dialysis should be used instead of peritoneal dialysis to remove the drug from the body. Research has not shown cefepime to have any negative effects on fertility or be carcinogenic or genotoxic.
image of a doctor in a lab doing drug, clinical research

Maxipime Novel Uses: Which Conditions Have a Clinical Trial Featuring Maxipime?

33 active trials are being conducted to determine the efficacy of Maxipime in treating Abdominal Infections, Bacterial Infections and Pneumonia.
Condition
Clinical Trials
Trial Phases
Urinary tract infection
0 Actively Recruiting
Pneumonia
0 Actively Recruiting
Abdominal Infection
0 Actively Recruiting
Urinary tract infection
0 Actively Recruiting
Pneumonia
32 Actively Recruiting
Phase 3, Not Applicable, Early Phase 1, Phase 2, Phase 1
Meningitis, Bacterial
0 Actively Recruiting
Urinary Tract Infection (UTI)
6 Actively Recruiting
Phase 1, Phase 3, Phase 4, Phase 2
Bacterial Infections
0 Actively Recruiting
Febrile Neutropenia
3 Actively Recruiting
Phase 2, Not Applicable
Pyelonephritis
1 Actively Recruiting
Not Applicable

Maxipime Reviews: What are patients saying about Maxipime?

4.3Patient Review
9/9/2009
Maxipime for Infection of Bone
I noticed that my urine has a very strong smell. At first I dismissed it but then realized it was the urine. The smell is like sour or metal. Am I the only one with this symptom? Well, besides the nasua and upset stomach?
3.7Patient Review
9/22/2007
Maxipime for Bacterial Urinary Tract Infection
I'm so sick of being sick all the time.
3.7Patient Review
11/4/2008
Maxipime for Pneumonia caused by the Bacteria Pseudomonas Aeruginosa
My young patient had a very high fever after taking this medication.
3.3Patient Review
4/6/2011
Maxipime for Bacterial Urinary Tract Infection
The side effects of this medication were eye irritation, itchiness, and loose stools. The good news is that it was easy to administer through my PICC line.
2Patient Review
11/25/2012
Maxipime for Bacterial Pneumonia caused by Klebsiella
I experienced extreme tiredness, lethargy, and depression while taking this medication. I was also unable to retain any information effectively due to the nature of the medication.
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about maxipime

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What type of drug is MAXIPIME?

"This drug belongs to a class of antibiotics called cephalosporins. It works by preventing the growth of bacteria."

Answered by AI

Is MAXIPIME a penicillin?

"Maxipime is an antibiotic used to treat many kinds of bacterial infections, including severe or life-threatening forms."

Answered by AI

What is MAXIPIME used for?

"Maxipime (cefepime hydrochloride) is a broad-spectrum cephalosporin antibiotic that can be used to treat many different kinds of bacterial infections, including severe or life-threatening forms."

Answered by AI

Is MAXIPIME and cefepime the same?

"The administration of MAXIPIME is a mixture of cefepime hydrochloride and L-arginine. It contains the equivalent of not less than 90 percent and not more than 115 percent of the labeled amount of cefepime."

Answered by AI

Clinical Trials for Maxipime

Have you considered Maxipime clinical trials? We made a collection of clinical trials featuring Maxipime, we think they might fit your search criteria.Go to Trials
Image of Children's Healthcare of Atlanta in Atlanta, United States.

Antibiotic Strategies for Pneumonia in Children

12 - 71
All Sexes
Atlanta, GA
The goal of this clinical trial is to determine if a "watch and wait" antibiotic strategy, called Safety Net Antibiotic Prescribing (SNAP), can safely reduce unnecessary antibiotic use while ensuring that children diagnosed with community-acquired pneumonia get better from their illness. The main aims of this study are: * To compare the effectiveness of SNAP versus immediate antibiotic prescribing in children with mild community-acquired pneumonia (CAP) * To identify which patient groups benefit most from the SNAP strategy * To identify factors that shape implementation of each prescribing strategy. Researchers will compare the SNAP strategy (where parents or guardians are instructed to give antibiotics only if their child is not improving after 72 hours, or sooner if they are worsening) to the immediate antibiotic prescribing strategy (where parents or guardians are instructed to give the antibiotics right after their healthcare visit) to see if one strategy is more effective than the other. Participants will be randomly assigned to either the immediate antibiotic group or the SNAP group at enrollment. Participation lasts 14 days with follow-up surveys at 4, 7, and 14 days after enrollment.
Recruiting
Has No Placebo
Children's Healthcare of Atlanta (+3 Sites)Todd Florin, MD, MSCE
Have you considered Maxipime clinical trials? We made a collection of clinical trials featuring Maxipime, we think they might fit your search criteria.Go to Trials
Image of Benioff Children's Hospital - Oakland in Oakland, United States.

Decision Support for Lower Respiratory Infections in Children

6 - 17
All Sexes
Oakland, CA
Eliminating inappropriate antibiotic use in pediatric lower respiratory tract infections (LRTI) is the central focus of this research. LRTIs (pneumonia, bronchiolitis, and infection-related exacerbations of asthma) account for nearly one-third of all emergency department (ED) visits and 40% of all infection-related hospitalizations in US children. LRTIs also account for more antibiotic use in children's hospitals than any other condition, despite most LRTIs being viral in nature. Inappropriate antibiotics are associated with substantial adverse effects. Accordingly, national guidelines strongly discourage routine antibiotic use for bronchiolitis and acute asthma and argue for significantly reducing antibiotic exposure (initiation, spectrum, and duration) in pneumonia. To address the problem of inappropriate antibiotic use, hospital-based antimicrobial stewardship programs (ASPs) are now common nationwide, and these programs have demonstrated effectiveness in some hospital settings. Unfortunately, traditional ASP approaches do not translate well to the fast-paced and unpredictable ED environment, and hospital-based ASP resources are finite and not always immediately available. Clinical decision support (CDS) embedded within the electronic health record (EHR) is a strategy that could address the ED antibiotic stewardship gap. Informed by a deep understanding of the key facilitators and barriers to using CDS to support appropriate antibiotic use in ED and hospital settings, the investigators have developed two stewardship-focused CDS interventions for pediatric LRTI. The overarching goal of this research is to rigorously evaluate the implementation and effectiveness of these CDS tools, alone and in combination, against usual care only in a pragmatic randomized clinical trial at 3 U.S. children's hospitals.
Recruiting
Has No Placebo
Benioff Children's Hospital - Oakland (+2 Sites)Derek J Williams, MD, MPH
Image of Harbor UCLA Medical Center - Medicine - Infectious Diseases in Torrance, United States.

Optimized Beta-lactam Dosing for Bacterial Infections

18+
All Sexes
Torrance, CA
The purpose of this study is to evaluate the abilities of Cystatin C (CysC) and CysC-based estimated Glomerular Filtration Rate (eGFR) equations to characterize the pharmacokinetics (PK) profiles of meropenem and cefepime relative to Serum Creatinine (SCR), Serum Creatinine based Equation (SCRE)and iohexol at the population and individual levels in critically ill adult patients with suspected or documented AMR Gram-negative infections. We hypothesize that CysC and CysC-based eGFR equations will characterize the PK profiles of meropenem and cefepime at the population and individual levels with greater accuracy and precision than SCR and SCREs. Iohexol will be administered to patients enrolled in the study and serve as the reference indicator of measured Glomerular Filtration Rate (mGFR), which is the gold standard assessment of kidney function. We hypothesize that the predictive performances of CysC and CysC-based eGFR equations in estimating the PK profiles of meropenem and cefepime at the population and individual levels will be comparable to iohexol. The information obtained in this study will be used to develop PK/pharmacodynamics (PD) optimized meropenem and cefepime dosing schemes based on the renal function biomarker population PK (PopPK) model with the best predictive performance for clinical use in the treatment of critically ill adult patients with suspected or documented AMR Gram-negative infections and varying degrees of renal function. The primary objective of this study is to compare the abilities of renal function biomarkers (CysC, CysC-based eGFR equations, SCR, SCREs) relative to iohexol to characterize the PK profiles of meropenem and cefepime in critically ill adult patients with suspected or documented AMR Gram-negative infections.
Phase 4
Recruiting
Harbor UCLA Medical Center - Medicine - Infectious Diseases (+9 Sites)
Image of Loma Linda University Medical Center Troesh Medical Campus in Loma Linda, United States.

Endotracheal Suctioning for Procedural Pain

18+
All Sexes
Loma Linda, CA
The goal of this experimental study is to understand if endotracheal tube (ETT) suctioning increases pain and causes stress on the body in intubated adult ICU patients. These patients are already on ventilators, which means they need suctioning to keep their airways clear, but this procedure may be uncomfortable and cause stress. The main questions this study aims to answer are: Does ETT suctioning raise pain levels as measured by the Critical-Care Pain Observation Tool (CPOT)? Does ETT suctioning increase certain chemicals in the blood (hypoxanthine, xanthine, and uric acid) that show stress and lack of oxygen in the body? Researchers will compare patients who have ETT suctioning (intervention group) with those who do not have suctioning during the study period (control group) to see if there are differences in pain and blood markers of stress. Participants will: Have pain measured before and after suctioning using the CPOT. Have blood samples taken from an existing line at three time points: 5 minutes before, 5 minutes after, and 30 minutes after suctioning. Provide demographic information (like age, gender, and diagnosis) from medical records. This research will help improve how pain is managed for ICU patients who cannot speak for themselves, potentially leading to better pain relief methods in the future.
Recruiting
Has No Placebo
Loma Linda University Medical Center Troesh Medical CampusElizabeth Johnston Taylor, PhD, FAAN
Have you considered Maxipime clinical trials? We made a collection of clinical trials featuring Maxipime, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security